Skip to content

Transcranial Direct Current Stimulation for Post-stroke Motor Recovery

TRANScranial Direct Current Stimulation for POst-stroke Motor Recovery - a Phase II sTudy (TRANSPORT 2)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03826030
Acronym
TRANSPORT 2
Enrollment
129
Registered
2019-02-01
Start date
2019-09-01
Completion date
2024-09-19
Last updated
2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motor Activity, Stroke, Ischemic, Upper Extremity Paralysis

Keywords

stroke, stroke recovery, brain stimulation, transcranial direct current stimulation

Brief summary

This research study is to find out if brain stimulation at different dosage level combined with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation technique is called transcranial direct current stimulation (tDCS). The treatment uses direct currents to stimulate specific parts of the brain affected by stroke. The adjunctive rehabilitation therapy is called modified Constraint-Induced Movement Therapy (mCIMT). During this therapy the subject will wear a mitt on the hand of the arm that was not affected by a stroke and force to use the weak arm. The study will test 3 different doses of brain stimulation in combination with mCIMT to find out the most promising one.

Interventions

DEVICESham

Sham group only receives 30 seconds of stimulation at 2mA in the beginning to create a sensory perception to the scalp in order to blind the subject.

DEVICELow dose tDCS

The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session

DEVICEHigh dose tDCS

The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session

BEHAVIORALmCIMT

All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Each subject must meet all of the following criteria to participate in this study: 1. 18-80 years old; and 2. First-ever unihemispheric ischemic stroke radiologically verified and occurred within the past 30-180 days; and 3. \>10° of active wrist extension, \>10° of thumb abduction/extension, and \> 10° of extension in at least 2 additional digits; and 4. Unilateral limb weakness with a Fugl-Meyer Upper Extremity score of ≤ 54 (out of 66) to avoid ceiling effects; and 5. An absolute difference of FM-UE scores between the two baseline assessments that is ≤ 2 points indicating stable motor impairment; if subject is not stable, then he/she will be invited for a reassessment after 7-14 days (but no more than 3 reassessments); and 6. Pre-stroke mRS ≤2; and 7. Signed informed consent by the subject or Legally Authorized Representative (LAR). Each Subject who meets any of the following criteria will be excluded from the study: 1. Primary intracerebral hematoma, subarachnoid hemorrhage or bi-hemispheric or bilateral brainstem ischemic strokes; 2. Medication use at the time of study that may interfere with tDCS, including but not limited to carbamazepine, flunarizine, sulpiride, rivastigmine, dextromethorphan; 3. Other co-existent neuromuscular disorders (pre- or post-stroke) affecting upper extremity motor function; 4. Other neurological disorders (pre- or post-stroke) affecting subject's ability to participate in the study; 5. Moderate to severe cognitive impairment defined as Montreal Cognitive Assessment (MOCA) score \< 18/30; 6. History of medically uncontrolled depression or other neuro-psychiatric disorders despite medications either before or after stroke that may affect subject's ability to participate in the study; 7. Uncontrolled hypertension despite medical treatment(s) at the time of randomization, defined as SBP≥185 mmHg or DBP≥110 mmHg (patient can be treated, reassessed and randomized later); 8. Presence of any MRI/tDCS/TMS risk factors including but not limited to: 8a) an electrically, magnetically or mechanically activated metallic or nonmetallic implant including cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system; 8b) a non-fixed metallic part in any part of the body, including a previous metallic injury to eye; 8c) pregnancy (effects of MRI, TMS, and tDCS on the fetus are unknown); 8d) history of seizure disorder or post-stroke seizure; 8e) preexisting scalp lesion under the intended electrode placement or a bone defect or hemicraniectomy; 9. Planning to move from the local area within the next 6 months; 10. Life expectancy less than 6 months; 11. Has received Botulinum toxin injection to the affected upper extremity in the past 3 months prior to randomization or expectation that Botulinum will be given to the Upper Extremity prior to the completion of the last follow-up visit; 12. Concurrent enrollment in another investigational stroke recovery study; 13. Doesn't speak sufficient English to comply with study procedures; 14. Expectation that subject cannot comply with study procedures and visits.

Design outcomes

Primary

MeasureTime frameDescription
Mean Change in FM-UE From BaselineDay 15The Fugl-Meyer Upper-Extremity (FM-UE) is a measure of motor impairment (0 to 66 points, with higher points indicating less impairment). FM-UE scale consists of a 33-item assessment which provides a global assessment of UE motor impairment. A rater provides an ordinal rating (2=near normal ability/response, 1=partial ability, 0=unable to perform/no response). The FM-UE scale is a proven scale with excellent intra-rater reliability (0.99), inter-rater reliability (0.99), test-retest reliability (0.94 -0.99), and internal consistency (0.97). FM-UE scale was assessed both by site raters (who were masked to the intervention) and by a central rater (who was masked to timepoint and intervention), by watching video recordings. The centrally rated score was used for the primary outcome analysis. For each element of the FM-UE scale, if the centrally rated score could not be determined, the site rater score was substituted.

Secondary

MeasureTime frameDescription
Mean Change in WMFT Time Score From BaselineDay 15The Wolf Motor Function Test (WMFT) is a measure of functional motor activity that quantifies upper extremity (UE) motor ability through timed and functional tasks. The WMFT Time Score the median of 15 timed arm movements and hand dexterity tasks, each to be completed in 120s. If a task could not be completed in 120s, a score of 121s was assigned. A lower WMFT Time Score is better.
Mean Change in SIS Hand Subscale From BaselineDay 15The Stroke Impact Scale (SIS) has 8 subscales which ask questions regarding a patient's physical limitations, memory and thinking, emotions and mood, ability to communicate, daily activities, mobility at home and in the community, use of hand most affected by stroke, and ability to participate in meaningful life activities. Each subscale item is rated on a scale from 5-1 (5= None of the time, 4=a little of the time, 3=Some of the time, 2=Most of the time, 1=All of the time). The domain/subscale scores, including the SIS Hand Subscale, range from 0 (worst) to 100 (best).

Countries

United States

Participant flow

Participants by arm

ArmCount
Sham tDCS + mCIMT
Sham tDCS + mCIMT group only receives 30 seconds of stimulation at 2mA in the beginning to create a sensory perception to the scalp in order to blind the subject. All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session.
43
2 mA tDCS + mCIMT
2 mA tDCS + mCIMT group receives direct current stimulation at 2 mA for 30 minutes per session. All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session.
43
4 mA + mCIMT
4 mA tDCS + mCIMT group receives direct current stimulation at 4 mA for 30 minutes per session. All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session.
43
Total129

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up111
Overall StudyToo busy to return for visits100
Overall StudyWithdrawal by Subject201

Baseline characteristics

Characteristic2 mA tDCS + mCIMT4 mA + mCIMTSham tDCS + mCIMTTotal
Age, Continuous62.0 years60.0 years56.0 years59.0 years
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants5 Participants3 Participants11 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
40 Participants38 Participants40 Participants118 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Fugl-Meyer Upper-Extremity (FM-UE) Scale39.0 units on a scale40.0 units on a scale39.0 units on a scale39.0 units on a scale
Lesion Volume - Affected Side (Centrally Assessed)2.5 centimeters cubed1.5 centimeters cubed1.4 centimeters cubed1.9 centimeters cubed
Log(WMFT Time Score)1.4 log(seconds)1.2 log(seconds)1.4 log(seconds)1.3 log(seconds)
Montreal Cognitive Assessment (MoCA)27.0 units on a scale26.0 units on a scale27.0 units on a scale27.0 units on a scale
NIH Stroke Scale (NIHSS)3.0 units on a scale3.0 units on a scale3.0 units on a scale3.0 units on a scale
Pre-Stroke Dominant Side
Left
4 Participants3 Participants3 Participants10 Participants
Pre-Stroke Dominant Side
Right
39 Participants40 Participants40 Participants119 Participants
Pre-Stroke Modified Rankin Scale (mRS)
0: No Symptoms At All
35 Participants35 Participants39 Participants109 Participants
Pre-Stroke Modified Rankin Scale (mRS)
1: No Significant Disability Despite Symptoms
4 Participants5 Participants1 Participants10 Participants
Pre-Stroke Modified Rankin Scale (mRS)
2: Slight Disability
4 Participants3 Participants3 Participants10 Participants
Presumed Motor Evoked Potential (MEP) Positive - Affected Side
No
12 Participants16 Participants10 Participants38 Participants
Presumed Motor Evoked Potential (MEP) Positive - Affected Side
Yes
31 Participants27 Participants32 Participants90 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants1 Participants0 Participants4 Participants
Race (NIH/OMB)
Black or African American
14 Participants19 Participants20 Participants53 Participants
Race (NIH/OMB)
More than one race
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants2 Participants0 Participants2 Participants
Race (NIH/OMB)
White
25 Participants21 Participants23 Participants69 Participants
Sex: Female, Male
Female
13 Participants19 Participants22 Participants54 Participants
Sex: Female, Male
Male
30 Participants24 Participants21 Participants75 Participants
Side of the Body Made Weak by the Index Stroke
Left
30 Participants17 Participants23 Participants70 Participants
Side of the Body Made Weak by the Index Stroke
Right
13 Participants26 Participants20 Participants59 Participants
Stroke Impact Scale (SIS) Hand Subscale30.0 units on a scale30.0 units on a scale25.0 units on a scale25.0 units on a scale
Time from Index Stroke to Randomization
30-90 Days
12 Participants11 Participants11 Participants34 Participants
Time from Index Stroke to Randomization
91-180 Days
31 Participants32 Participants32 Participants95 Participants
Weighted Corticospinal Tract (wCST) Lesion Load - Affected Side (Centrally Assessed)0.5 centimeters cubed0.6 centimeters cubed0.5 centimeters cubed0.5 centimeters cubed
Wolf-Motor Functional Test (WMFT) Time Score4.0 seconds3.3 seconds3.9 seconds3.8 seconds

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 430 / 430 / 43
other
Total, other adverse events
4 / 431 / 435 / 43
serious
Total, serious adverse events
2 / 430 / 435 / 43

Outcome results

Primary

Mean Change in FM-UE From Baseline

The Fugl-Meyer Upper-Extremity (FM-UE) is a measure of motor impairment (0 to 66 points, with higher points indicating less impairment). FM-UE scale consists of a 33-item assessment which provides a global assessment of UE motor impairment. A rater provides an ordinal rating (2=near normal ability/response, 1=partial ability, 0=unable to perform/no response). The FM-UE scale is a proven scale with excellent intra-rater reliability (0.99), inter-rater reliability (0.99), test-retest reliability (0.94 -0.99), and internal consistency (0.97). FM-UE scale was assessed both by site raters (who were masked to the intervention) and by a central rater (who was masked to timepoint and intervention), by watching video recordings. The centrally rated score was used for the primary outcome analysis. For each element of the FM-UE scale, if the centrally rated score could not be determined, the site rater score was substituted.

Time frame: Day 15

Population: Modified intent to treat population which included all subjects with any post-baseline data.

ArmMeasureValue (LEAST_SQUARES_MEAN)
Sham tDCS + mCIMTMean Change in FM-UE From Baseline4.91 units on a scale
2 mA tDCS + mCIMTMean Change in FM-UE From Baseline3.87 units on a scale
4 mA + mCIMTMean Change in FM-UE From Baseline5.53 units on a scale
Comparison: The null hypothesis was no overall difference in FM-UE scale change between the three groups on day 15. The change in FM-UE was modelled using a linear mixed-effects repeated measures model adjusted for visit (ie, day 15, day 45, and day 105), treatment group, treatment group by visit interaction, baseline FM-UE, time from stroke (30-90 vs. 91-180 days), and enrolment site. An AR(1) autocorrelation structure was used for visit, and variance components structure for sites.p-value: 0.39Mixed Models Analysis
Secondary

Mean Change in SIS Hand Subscale From Baseline

The Stroke Impact Scale (SIS) has 8 subscales which ask questions regarding a patient's physical limitations, memory and thinking, emotions and mood, ability to communicate, daily activities, mobility at home and in the community, use of hand most affected by stroke, and ability to participate in meaningful life activities. Each subscale item is rated on a scale from 5-1 (5= None of the time, 4=a little of the time, 3=Some of the time, 2=Most of the time, 1=All of the time). The domain/subscale scores, including the SIS Hand Subscale, range from 0 (worst) to 100 (best).

Time frame: Day 15

ArmMeasureValue (MEAN)
Sham tDCS + mCIMTMean Change in SIS Hand Subscale From Baseline25.24 score on a scale
2 mA tDCS + mCIMTMean Change in SIS Hand Subscale From Baseline13.60 score on a scale
4 mA + mCIMTMean Change in SIS Hand Subscale From Baseline21.51 score on a scale
Secondary

Mean Change in WMFT Time Score From Baseline

The Wolf Motor Function Test (WMFT) is a measure of functional motor activity that quantifies upper extremity (UE) motor ability through timed and functional tasks. The WMFT Time Score the median of 15 timed arm movements and hand dexterity tasks, each to be completed in 120s. If a task could not be completed in 120s, a score of 121s was assigned. A lower WMFT Time Score is better.

Time frame: Day 15

ArmMeasureValue (MEAN)
Sham tDCS + mCIMTMean Change in WMFT Time Score From Baseline-8.67 score on a scale
2 mA tDCS + mCIMTMean Change in WMFT Time Score From Baseline-1.65 score on a scale
4 mA + mCIMTMean Change in WMFT Time Score From Baseline-10.37 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026